As previously disclosed, WntResearch has been requested to perform an initial safety assessment as part of the approval process for the study"s initiation, since ten patients have undergone surgery during the Foxy-5 administration period.  The DSMB group consists of highly experienced clinical researchers: Professor Jan Vermorken, Professor Andrés Cervantes and Dr Ramon Salazar, together with MS-oncology"s Chief Medical Officer, Stephan Winckels. All of them consider the side effect profile to be favorable.  The rate of reported side effects which are considered to be attributable to the use of Foxy-5 is low. All of these side effects are mild, and not recurring in continued treatment. No patients have terminated the study due to side effects.  

"This first safety analysis on patients within the target group strengthens our assessment that Foxy-5 is a safe product, and confirms the outcome of previous toxicological studies. The result is significant for primarily two reasons; that Foxy-5 can be administered without risk to otherwise healthy cancer patients, and that Foxy-5 so far has not shown any indication to affect the healing process after surgery. A safe product, practically void of side effects, is a prerequisite to secure approval as a future neoadjuvant treatment for patients," says WntResearch"s CEO, Peter Morsing.

For more information, please contact:

Peter Morsing, CEO, WntResearch AB
E-mail: pm@wntresearch.com

Telephone: +46 727 200711

This information is information that WntResearch AB is obliged to make public

pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency

of the contact person set out above, on December 20, 2019.

About WntResearch

WntResearch is developing an entirely new kind of cancer drug, which inhibits the tumour cells" ability to spread through the body and metastasize. The majority of cancer deaths are due to metastases, and there are no therapies available that can prevent that. Foxy-5, the Company"s most advanced drug candidate, is a peptide that mimics the body"s own WNT5A protein. In preclinical trials, Foxy-5 has demonstrated ability to suppress the mobility and invasive power of cancer cells, and thus to inhibit metastasis. Phase 1 studies on patients with colon, prostate and breast cancer have demonstrated a good safety profile and favourable pharmacokinetics, and early data indicates biological activity. A Phase 2 multicenter study was recently initiated on patients with colon cancer, in order to study the anti-metastasizing efficacy of Foxy-5. WntResearch"s share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com